Get started

CLVS

CLVS signs of Life? Break outAfter following this since hit flat lined at .81 cent I saw clear cut signs of accumulation and break out. Right at the end of the option chain cycle. Which ended today. The fact that it jumped to above a $1 on this day shows to me that its serious about bouncing off the bottom. Otherwise it could have just stayed below $1 until after today. It jumping above a dollar today means someone lost money or that they dragged it so far down that even if it came up it didnt matter..... Now we have a full month in this option call to run. does it go parabolic? or does it re-accumulate from here to inch its way back up? i marked two key areas in blue for when obvious change tot he price action can happen. by iCantw84it 06.17.22
CLong
by iCantw84it
1
Clovis | 3 buy scenarios | One trial at a timeGreat run Clovis had the last days. However i prefer not to buy into runs and wait till my requirements are met. I marked 3 possible places where i would buy if the following would happen: - Price gets above the level - Open and close of a monthly candle above the level, then buy - Targets are based on the next resistance level - Stop- Loss: None Good luck Disclaimer: - This information does not constitute as financial advice and is only for educational purposes. I am not your financial advisor. - You trade entirely at your own risk - Make your own research - Finance and trading is evil, capitalism is bad, duh ;)
CLong
by a_tale_of_bulls_and_bears
2
Clovis Oncology CLVS Option CallsBased on my research, I think that the $3 strike price expiring July 15, with the price of $0.21 or lower is what I would pick right now. As you know, the OTM options can be profitable even if they don`t reach the strike price. If the stock moves closer to the strike price after you enter the trade, or if there is a rapid increase in Implied Volatility, you can sell the option for a profit. My personal goal is to transform $10k into $1Million from options trading. Thank you for viewing my out of the money option calls and puts ideas!
CLong
by CryptoCopyTrading
Clovis Oncology Curing it. CLVSAnother bullish looking pick in the same industry. We love impulses, especially we catch them before tehy make themselves apparent. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
CLong
by Rykin_Capital
CLVSClovis Oncology Inc (NASDAQ:CLVS) has been in a tremendous tailspin the last three weeks. The stock has seen a bevy of selling bring the stock to fresh new lows for the year and near historical lows. However, the last two trading sessions reveal an increase in volume, suggesting some capitulation and I think that a sharp rally could follow over the next few days. At $3.38 a share, and considering this stock was trading well over $4.50 last month, the risk for further decline is outweighed by the potential gain an explosive bounce would provide. Plus, historically the stock reacts violently to the upside every time the RSI reaches extreme oversold levels. In fact, this stock is also a short squeeze play. Keep an eye on it next week, it should mount a violent rally from here IMHO. Last week the company said that it expects cash resources, and revenues and available financing sources to be enough to support its operations for at least the next 12 months.
CLong
by SmoothJB
CLVS back on the low lowCLVS is now back at its November 2020 low. The interesting part of this trend is that it also managed to test, hold, and bounce off of an almost identical level (strong support?). As of Friday afternoon shares retested an interim area of higher traffic that was support earlier in August and late July but now appears to have become a resistance level over the last 3 sessions at least. With the "short squeeze stocks" conversation building steam, it could be interesting for CLVS. Finviz shows the short float percentage at 27% right now. " The biotech sector may also host some of the other heavily shorted stocks. Phase trial data, scientific reports, and the like all play a role in directional momentum. In this case, Clovis has felt some pressure over the last few quarters. Clinical data on its FAP-2286 platform, along with missed earings, haven’t helped the cause. Then you’ve got news of large, multi-million dollar fundraising initiatives adding more pressure as well. Needless to say, it has happened to hopefully advance the company’s pipeline...Clovis specializes in developing cancer treatments. Its lead candidate Rubraca is an oral treatment being developed in multiple types of tumors. These include ovarian and prostate cancers. It’s approved in the US for maintenance treatment in adults with recurrent epithelial, ovarian, fallopian tube, or primary peritoneal cancers...As far as CLVS being considered one of the “short squeeze stocks,” outlets show that the penny stock’s short-interest sits around 27%. Of course, it isn’t as high as some of the others on this list. However, anything over 20%, by most accounts, can be considered high. " Quote Source & Read More: 4 Short Squeeze Penny Stocks To Watch After SPRT Stock’s 1,309% Run
C
by PennyStocks101
CLVS 786 Fib Line Holding (For Now)Took the chart back out to March of last year to do a little fib retracement. Wouldn't you know, CLVS has been channel bound for a minute between the 618 and 786 fib lines with pretty clear support and resistance levels at each. Since it retraced back to the 786 again and is holding (for now), volume is likely going to be the "friend" or "foe" depending on how you're looking to trade this stock. You've also got the 50DMA to keep track of, which has also been a decent level of resistance over the past week or so. Fundamentally, I'm looking to see if speculation starts building later down the line after they announced that they initiated sponsored clinical development of FAP-2286 with the Phase 1/2 LuMIERE clinical trial in patients with FAP-positive solid tumors which is now enrolling. Either way, cancer stocks seem to be picking up some steam . Whether it's targeted treatments or drug delivery technology, oncology is beginning to take its own slice of biotech lately.
C
by PennyStocks101
CLVS - Cure for the market cancer!This company is going to be huge. Fundamentally : It's already passing the Phase 3 ARIEL4 study. Revenue has been beaten in last quarter report. (although there was a small overestimate for the profit(loss) per share) The MACD indicator is bouncing back (also the price is pushing through the Moving Averages). Price is now in the channel (2 thick red dot lines). It's rebouncing from the resistance(green line coming from the bottom). RSI + MF looking good! Divergance indicator is saying it's going to rise! Remember : not financial advise, just see what's going to happen. Use fundamentals to find a stock, use technicals to find moment to buy it. Good luck!
CLong
by MateuszZakrzewski
6
It's unbelievable where this is sitting right now..This is a nice example of how following who's involved can lead to excellent opportunities. Just look at $SAVA. In the Christmas months of 2019, multiple insiders were seen purchasing $100's of thousands worth of shares immediately before the share price skyrocketed several hundred percent. Fast forward 13 months later, and the price broke $100.. Still, many times, you question whether these sharp intraday rallies are the product of market manipulation, as they always seem to happen immediately before heavy sell offs, but who knows..
NASDAQ:NVAX
by stocktradez6
$CLVS Triangular TIPZ close to the X'zCLOVIS maker of FDA approved Rubraca® which is a treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy. www.rubraca.com Sitting at a pretty interesting area right now, sure it will get some more movement soon as we are at a crucial area. Plus last time I reviewed the sec docs it seemed to me like they were lowering net-losses & striving towards profits. DYI: www.sec.gov
CLong
by AaronX